Data Sheet 1_Sintilimab plus fruquintinib with or without radiotherapy for third-line trea

A 2026 study protocol outlines a multicenter, randomized controlled phase II trial evaluating third-line treatments for microsatellite stable colorectal cancer with liver metastases. The trial compares sintilimab plus fruquintinib with or without liver-directed radiotherapy against fruquintinib alone. Primary endpoints include progression-free survival, with secondary endpoints of objective response rate, disease control rate, overall survival, and safety.

Use Cases

• Designing similar clinical trials based on the described patient selection criteria and randomization scheme.
• Analyzing the efficacy of combined immunotherapy, targeted therapy, and radiotherapy for liver metastases.
• Comparing safety profiles of different treatment regimens for metastatic colorectal cancer.
• Assessing the role of stereotactic body radiation therapy and low-dose radiation therapy in oligometastatic and multiple metastatic disease.

Strengths

• The protocol is registered with clinicalTrials.gov (identifier NCT06356584), providing a public reference.
• Specific radiation dosing regimens are detailed for different metastasis presentations.
• Clear primary and secondary endpoints are defined for measuring efficacy and safety.

Limitations

• The dataset is a PDF study protocol (110.2 KB), not the resulting clinical trial data.
• Column-level documentation for any eventual trial data is absent.
• Freshness should be verified as the last update date is in the future (2026-05-12).

Provenance

Source

figshare, authored by Zhenyu Ma.

Collection Method

A published clinical trial study protocol.

Freshness

Last updated 2026-05-12 05:42:18

Geography

Multicenter trial; specific locations not stated.